Acupoint application for exogenous fever: a multi-central retrospective cohort study.
10.13703/j.0255-2930.20210330-k0005
- Author:
Rui LI
1
,
2
,
3
,
4
;
Qing-Na LI
1
,
2
,
5
;
Fang LU
1
,
2
,
5
;
Ming-Jie ZI
1
,
2
,
5
;
Chen-Fei LI
1
,
2
,
5
;
Rui GAO
1
,
2
,
5
Author Information
1. Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
2. NMPA for Laboratory for Clinical Research and Evaluation of Traditional Chinese Medicine, Beijing 100091
3. National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091
4. Postdoctoral Work Station of Yabao Pharmaceutical Group Co., Ltd., Yuncheng 044000, Shanxi Province.
5. National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091.
- Publication Type:Journal Article
- Keywords:
acupoint application;
application prescription;
cohort study;
effectiveness;
exogenous fever
- MeSH:
Acupuncture Points;
Child;
Child, Preschool;
Drugs, Chinese Herbal/therapeutic use*;
Fever/therapy*;
Humans;
Retrospective Studies;
Seasons
- From:
Chinese Acupuncture & Moxibustion
2022;42(4):390-396
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the effectiveness on exogenous fever and the characteristics of effective population, as well as the specialties of prescription of acupoint application.
METHODS:Using the internet electronic diagnosis and treatment platform (Spring Broadcast Wanxiangyun Clinic Database, and the main TCM suitable technology promoted by this platform is acupoint application therapy), from August 24, 2020 to November 5, 2020, the patients complained with fever and diagnosed as common cold, with a record of initial visit and at least one return visit, were included as the subjects. According to whether acupoint application therapy was received or not, the subjects were divided into an exposure group (with acupoint application therapy, 26 664 cases) and a non-exposure group (without acupoint application therapy, 515 cases). Using the propensity score, the mixed factors, e.g. age and sex, were matched between the two groups. The disappearance rate of fever (within 2 days) and the time for the first fever disappearance were taken as the effect indexes. The association rules extraction was adopted to analyze the characteristics of effective population and acupoint application prescription in treatment of exogenous fever.
RESULTS:After propensity score matching, there were 1 229 cases in the application group and 423 cases in the non-application group. The disappearance rate of fever in the application group was 1.82 times as high as that in the non-application group (P<0.05). The time for the first fever disappearance in the application group was shorter than the non-application group (P<0.01). A total of 5 370 cases were effective with acupoint application therapy, of which, the median age was 2 years old and the proportion of children patients under 6 years old was relatively high. In the effective crowd, the most commonly-used acupoints were Shenque (CV 8), Dazhui (GV 14), Yongquan (KI 1) and Tiantu (CV 22), etc. Shenque (CV 8) and Dazhui (GV 14) were highly associated and the support was 62.57%. The most common herbal materials in the acupoint application therapy included Radix et Rhizoma Rhei, Natrii Sulfas, Radix Scutellariae, Herba Ephedrae and Radix Bupleuri, etc. Radix et Rhizoma Rhei and Natrii Sulfas were most commonly used at Shenque (CV 8) and the supports were 57.49% and 57.21% respectively. Herba Ephedrae was most commonly applied to Shenque (CV 8) and Dazhui (GV 14) and the supports were 48.21% and 43.91% respectively. Radix Bupleuri was the most common herb at Dazhui (GV 14) with the support of 46.61%. Besides, the most commonly combined western drugs included cefixime and keteling in the acupoint application therapy and the supports were 13.07% and 12.72% respectively.
CONCLUSION:Acupoint application is effective on exogenous fever. The common therapy refers to Radix et Rhizoma Rhei and Natrii Sulfas plaster at Shenque (CV 8), while Herba Ephedrae and Radix Bupleuri at Dazhui (GV 14).
